Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.celrep.2021.108837 http://scihub22266oqcxt.onion/10.1016/j.celrep.2021.108837 33662255!7901292!33662255     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33662255&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cell+Rep 2021 ; 34 (10): 108837 Nephropedia Template TP {{tp|p=33662255|t=2021. Use of convalescent serum reduces severity of COVID-19 in nonhuman primates |pdf=|usr=}}{{33662255}} gab.com Text Use of convalescent serum reduces severity of COVID-19 in nonhuman primates JO: Cell Rep http://www.kidney.de/pget.php?&tw=1&pmid=33662255 #FOAvip Passive transfer of convalescent plasma or serum is a time-honored strategy for treating infectious diseases. Human convalescent plasma containing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently being used to treat patients with coronavirus disease 2019 where clinical efficacy trials are ongoing. Here, we assess therapeutic passive transfer in groups of SARS-CoV-2-infected African green monkeys with convalescent sera containing either high or low anti-SARS-CoV-2 neutralizing antibody titers. Differences in viral load and pathology are minimal between monkeys that receive the lower titer convalescent sera and untreated controls. However, lower levels of SARS-CoV-2 in respiratory compartments, reduced severity of virus-associated lung pathology, and reductions in coagulopathy and inflammatory processes are observed in monkeys that receive high titer sera versus untreated controls. Our data indicate that convalescent plasma therapy in humans may be an effective strategy provided that donor sera contain high anti-SARS-CoV-2 neutralizing titers given in early stages of the disease. Twit Text FOAVip Use of convalescent serum reduces severity of COVID-19 in nonhuman primates ????Cell Rep http://www.kidney.de/pget.php?&tw=1&pmid=33662255 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33662255 #FOAvip English Wikipedia <ref>{{Cite pmid|33662255}}</ref> Use of convalescent serum reduces severity of COVID-19 in nonhuman primates #MMPMID33662255 Cross RW; Prasad AN; Borisevich V; Woolsey C; Agans KN; Deer DJ; Dobias NS; Geisbert JB; Fenton KA; Geisbert TW Cell Rep 2021[Mar]; 34 (10): 108837 PMID33662255show ga Passive transfer of convalescent plasma or serum is a time-honored strategy for treating infectious diseases. Human convalescent plasma containing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently being used to treat patients with coronavirus disease 2019 where clinical efficacy trials are ongoing. Here, we assess therapeutic passive transfer in groups of SARS-CoV-2-infected African green monkeys with convalescent sera containing either high or low anti-SARS-CoV-2 neutralizing antibody titers. Differences in viral load and pathology are minimal between monkeys that receive the lower titer convalescent sera and untreated controls. However, lower levels of SARS-CoV-2 in respiratory compartments, reduced severity of virus-associated lung pathology, and reductions in coagulopathy and inflammatory processes are observed in monkeys that receive high titer sera versus untreated controls. Our data indicate that convalescent plasma therapy in humans may be an effective strategy provided that donor sera contain high anti-SARS-CoV-2 neutralizing titers given in early stages of the disease. |Animals[MESH] |Antibodies, Neutralizing/blood[MESH] |Antibodies, Viral/blood[MESH] |COVID-19 Serotherapy[MESH] |COVID-19/immunology/*therapy/*veterinary/virology[MESH] |Chlorocebus aethiops/immunology[MESH] |Female[MESH] |Immunization, Passive/methods/veterinary[MESH] |Male[MESH] |Primate Diseases/immunology/*therapy/*virology[MESH] |Primates/immunology[MESH] |SARS-CoV-2/*immunology[MESH]Use of convalescent serum reduces severity of COVID-19 in nonhuman pri(epmc).pdf DeepDyve Pubget Overpricing